Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Why your co-pay for weight loss drugs like Wegovy just went through the roof
Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.
Medicare moves to expand coverage for weight-loss drugs Wegovy, Zepbound
The Biden administration is proposing a major expansion of how Medicare and Medicaid cover the weight-loss drugs Wegovy and Zepbound.
Weight Loss Drugs Linked to Decreased Alcohol Use
Taking weight loss drugs like Wegovy and Zepbound can help people cut back on what they eat and also on what they drink – including alcohol.
West Virginia leaders embrace effects of weight loss drugs, while also considering cost
The outgoing Biden administration is proposing to have popular weight-loss drugs like Wegovy or Zepbound covered by Medicare or Medicaid.
Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Study participants treated with Zepbound lost 20% of their body weight. A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight loss is most effective at helping people lose more weight in less time.
Eli Lilly’s Zepbound Outperforms Competitor in Weight Loss Trial, Supporting Buy Rating
Leerink Partners analyst David Risinger has reiterated their bullish stance on LLY stock, giving a Buy rating on December 2.Don't Miss our
Lilly to Boost Weight-Loss Drug Supply With $3 Billion Expansion
Eli Lilly & Co. is spending another $3 billion to build out its US manufacturing footprint as it ramps up production of its blockbuster diabetes and weight-loss drugs.
Eli Lilly Chief Scientific Officer explains Zepbound's weight loss advantage
Dan Skovronsky, Eli Lilly Chief Scientific Officer, joins 'Fast Money' to talk Zepbound's recent trial results and what it means for Eli Lilly's future growth.
Zepbound vs. Wegovy: New clinical trial says this weight-loss medication sheds more pounds
Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide), a product of Global 500 company Novo Nordisk, in a 2023–24 randomized clinical trial backed by Lilly.
wjactv on MSN
13h
New weight management clinic opens in Somerset, offering personalized health care services
A new comprehensive medical weight management program has opened its doors in Somerset, aiming to provide personalized care ...
4d
Weight-loss drugs deliver life-changing health benefits - and big profits
State measures now seek to remove barriers to weight-loss drugs, as demand for the meds skyrockets amid rising concerns about ...
The Associated Press on MSN
10d
Cheap Ozempic? How millions of Americans with obesity may get access to costly weight-loss drugs
Millions of obese Americans would get access to popular weekly injectables that would help them shed pounds quickly if a $35 ...
2d
Postpartum Weight Loss: 3 Steps to Get Started (& More Tips & Tricks)
Postpartum weight loss can feel impossible at times, especially if the weight isn’t coming off as quickly as you expected.
West Virginia MetroNews
3d
Weighing West Virginia’s weight loss options
West Virginia’s Public Employee Insurance Agency (PEIA) is in a bind. Medical inflation continues to drive up health care costs and the PEIA finance board is looking for ways to save money while ...
11d
on MSN
West Virginia residents struggle to afford GLP-1 weight loss drugs after state ends subsidy program
In 2020, West Virginia launched a pilot program to subsidize GLP-1 drugs for public employees, but the program was shuttered ...
Endocrinology Advisor
3d
Self-Stigma Linked to Greater Dropout, Engagement in Weight Loss Program
Self-stigma was associated with higher dropout rates, engagement, and weight loss among individuals who completed a weight loss program.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback